Acquired haemophilia is characterized by the development of autoantibodies specifically directed against the procoagulant activity ofthe factor VIII molecule in subjects without congenital haemophilia. The incidence of this disorder is about I to 5 per million population annually (1). Bleeding diathesis in these patients is often severe and potentially life-threatening and requires . early laboratory detection and treatment to eliminate inhibitors. A prolonged partial thromboplastin time (PTT), a normal prothrombin time (PT), and the lack of correction with normal plasma, associated with an acquired bleeding disorder, should raise further laboratory tests, including the demonstration of low factor FVIII levels in plasma with a high titre offactor VIII inhibitors (1). About half of the patients with acquired haemophilia have associated systemic disease (2,3) The first case of acquired haemophilia in a patient treated with warfarin has recently been reported (4).
Here we describe the first case of acquired haemophilia during heparin therapy. A 69-yearold man was admitted to the Division ofHematology in January 2000 because of an imposing haemorrhagic syndrome. His medical history included: aortic stenosis that had led to aortic valve replacement in October 1990 and warfarin treatment since then. On admission the patient was in treatment with calcium-heparin (12.500 VI bid, s.c.), rather than warfarin, because ofa chemical esophagitis due to accidental ingestion of caustic.
Physical examination showed bilateral leg and arm muscular haematomas and diffuse mild abdominal tenderness with no organomegaly. Laboratory findings on admission revealed: haemoglobin, 6.5 g/dl; prolonged PTT (81.8 s), with a ratio of 2.33; normal PT, fibrinogen levels and platelet count. The patient was treated immediately with protamine hydrochloride 50 mgl iv, but despite this treatment, PTT and the mixing test with normal plasma remained prolonged. Factor VIII acti vity was < I % and factor VIII inhibitor (4 BVlml) was identified. Additional tests to exclude conditions known to be associated with secondary acquired haemophilia (antinuclear factor, anti-DNA antibodies, lupus anticoagulant, anticardiolipin antibodies, hepatitis Band C antibodies, HIV, blood and urine cultures, chest and abdominal CT scan, prostatic biopsy, bone marrow biopsy) were negative. Thus, the patient was diagnosed with primary acquired haemophilia. The haemorrhagic syndrome was controlled by treatment with plasmatic factor FVIII (20.000 Units in bolus, followed by 7.000-10.000 Vld for 2 weeks), highdoses of immunoglobulins (70 g for 2 days) and desmopressin (20 mgldie for 2 days, s.c.). In addition, the patient was treated with plasmaexchange and was trasfused with 8 units of packed red blood cells to correct anaemia. Moreover, therapy with prednisone (1 gr. for three consecutive days followed by an orally administered maintenance dose of 50 mg/d) and ciclofosfamide (1650 mg every 15 days for 2 times, followed by maintenance dose of 100 mg/die), was started and the patient showed a complete clinical and immunological response. After a six-months therapy, no factor VIII inhibitor was detected in serum, and factor FVIII activity progressively raised to 100%. Immunosuppressive therapy went on for a further month.
Acquired haemophilia is a rare and potentially life-threatening illness caused by the development of antibodies against FVIII. The inhibitor may occur in association with immunological diseases, malignancies, lymphoproliferative disorders, and post partum, but in about half of the cases it occurs in patients without an underlying disease. Immunosuppressive treatment has been used to obtain elimination of the inhibitors but a prompt diagnosis and an effective treatment of bleeding symptoms are needed to prevent potentially lifethreatening consequences. On admission, no attempt was done to detect factor FVIII inhibitors because the patient was on heparin therapy. However, PTT prolongation after treatment with protamine hydrochloride led us to a delayed diagnosis of acquired haemophilia. Thus, higher awareness of such a complex bleeding disorder is needed for an earlier diagnosis, especially when a diagnosispostponing element such as heparin treatment is present.
